Secondary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome Following Allo‐ HCT : Features, Outcomes, and Risk Stratification
European Journal of Haematology · 2026-07 · 117 (1) · 192-199
DOI: 10.1111/ejh.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 25.03.2026. Verfasst von Nikita Volkov und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation, RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS) is a rare but highly fatal complication after allogeneic hematopoietic cell transplantation (allo‐HCT), frequently diagnosed under conditions of clinical uncertainty. We aimed to characterize post‐transplant sHLH/MAS and to identify clinically accessible factors associated with early mortality.
Methods
We retrospectively analyzed adult patients who developed sHLH/MAS after allo‐HCT between 2018 and 2025. Inclusion required an HScore ≥ 169. Overall survival within 60 days from sHLH/MAS onset was the primary endpoint. Clinical and laboratory variables were evaluated using Cox proportional‐hazards models, and patients were stratified according to the number of adverse prognostic factors identified.
Results
Seventy‐two patients met inclusion criteria. Median time from allo‐HCT to sHLH/MAS onset was 22 days. Sixty‐day overall survival was poor. In univariable and multivariable analyses, vasopressor‐dependent sepsis (HR 7.77, p < 0.001) and ferritin > 15 000 μg/L (HR 3.48, p = 0.002) were independently associated with early mortality. Stratification based on these two factors separated patients into low‐, intermediate‐, and high‐risk groups with 60‐day survival of 92%, 52%, and 9%, respectively ( p < 0.001).
Conclusions
Post‐transplant sHLH/MAS is associated with extremely high early mortality. Vasopressor‐dependent sepsis and extreme hyperferritinemia identify patients at particularly high risk. These findings require confirmation in independent cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone Marrow Transplantation, RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
ORCID-Profile: Nikita Volkov, Ivan Moiseev, Maria Krivitskaya, Dmitrii Zhogolev, Maria Vladovskaya, Yulia Vlasova, Sergey Bondarenko, Tatiana Rudakova, Svetlana Ziganshina, Aleksandr Siniaev, Anastasia Beynarovich, Kseniia Afanaseva, Elena Morozova, Alexander Kulagin
Zitieren
APA
Volkov, N., Moiseev, I., Krivitskaya, M., Zhogolev, D., Vladovskaya, M., Vlasova, Y., Bondarenko, S., Rudakova, T., Ziganshina, S., Siniaev, A., Beynarovich, A., Afanaseva, K., Morozova, E., & Kulagin, A. (2026). Secondary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome Following Allo‐ HCT : Features, Outcomes, and Risk Stratification. European Journal of Haematology, 117(1), 192-199. https://doi.org/10.1111/ejh.70173
Vancouver
Volkov N, Moiseev I, Krivitskaya M, Zhogolev D, Vladovskaya M, Vlasova Y, et al. Secondary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome Following Allo‐ HCT : Features, Outcomes, and Risk Stratification. European Journal of Haematology. 2026;117(1):192-199. doi:10.1111/ejh.70173
BibTeX
@article{Volkov2026,
author = {Volkov, Nikita and Moiseev, Ivan and Krivitskaya, Maria and Zhogolev, Dmitrii and Vladovskaya, Maria and Vlasova, Yulia and Bondarenko, Sergey and Rudakova, Tatiana and Ziganshina, Svetlana and Siniaev, Aleksandr and Beynarovich, Anastasia and Afanaseva, Kseniia and Morozova, Elena and Kulagin, Alexander},
title = {Secondary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome Following Allo‐ HCT : Features, Outcomes, and Risk Stratification},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {192--199},
doi = {10.1111/ejh.70173}
}
EUVIMED